Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma PatientsReport as inadecuate

Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients - Download this document for free, or read online. Document in PDF available to download.

Clinical and Developmental ImmunologyVolume 2012 2012, Article ID 290536, 8 pages

Clinical Study

The Ella Institute for Treatment and Research of Melanoma and Skin Cancer, The Sheba Cancer Research Center, The chaim Sheba Medical Center, Tel Hashomer 52621, Israel

Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel

Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Talpiot Medical Leadership Program, The chaim Sheba Medical Center, Tel Hashomer, Israel

Received 30 June 2011; Revised 26 September 2011; Accepted 28 September 2011

Academic Editor: Tetsuya Nakatsura

Copyright © 2012 Sapoznik Sivan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The search for melanoma biomarkers is crucial, as the incidence of melanoma continues to rise. We have previously demonstrated that serum CEACAM1 sCEACAM1 is secreted from melanoma cells and correlates with disease progression in metastatic melanoma patients. Here, we have used a different cohort of melanoma patients with regional or metastatic disease , treated with autologous vaccination. By monitoring sCEACAM1 in serum samples obtained prior to and after vaccination, we show that sCEACAM1 correlates with disease state, overall survival, and S100B. The trend of change in sCEACAM1 following vaccination increase-decrease inversely correlates with overall survival. DTH skin test is used to evaluate patients’ anti-melanoma immune response and to predict response to vaccination. Importantly, sCEACAM1 had a stronger prognostic value than that of DTH, and when sCEACAM1 decreased following treatment, this was the dominant predictor of increased survival. Collectively, our results point out the relevance of sCEACAM1 in monitoring melanoma patients.

Author: Sapoznik Sivan, Faranesh Suzan, Ortenberg Rona, Hamburger Tamar, Barak Vivian, Peretz Tamar, Schachter Jacob, Markel Gal, 



Related documents